Posts

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Eli Lilly partners with Oura to support GLP-1 patients via smart‑ring tools

on

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on

With ADA 2026 data in the books, analysts say Lilly is widening its lead in the obesity race

on

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

on

Lilly Highlights Low-Dose Zepbound and Foundayo for Long-Term Weight Loss Maintenance

on

Eli Lilly Invests Additional $4.5B in Indiana Manufacturing Facilities at LEAP District

on

Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

Trump Administration Indefinitely Delays Medicare Weight-Loss Drug Pilot Program

on

Eli Lilly Launches Employer Connect Platform to Expand GLP-1 Obesity Drug Access

on

Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval

on

Novo Nordisk's CagriSema Underperforms Eli Lilly's Zepbound in Head-to-Head Phase 3 Obesity Trial

on

Eli Lilly Reports Positive TOGETHER-PsO Trial Results for Taltz and Zepbound Combination in Psoriasis and Obesity

on

Eli Lilly Beats Sales Forecasts and Targets Major 2026 Growth, Outpacing Novo Nordisk

on

FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels

on

Arrowhead's RNAi Obesity Programs ARO-INHBE and ARO-ALK7 Advance with Encouraging Phase 1/2a Data

on

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

on

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly

on

Lilly Slightly Lowers Self-Pay Prices for Single-Dose Vials of Zepbound

on

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

on